Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Neurology > AAN 2019 > Alzheimer's Disease and other Dementias > Tight blood pressure control lowers risk of mild cognitive impairment

Tight blood pressure control lowers risk of mild cognitive impairment

Presented by
Dr Jeff Williamson, Wake Forest Baptist Medical Center, Winston-Salem, USA
Conference
AAN 2019
Trial
SPRINT MIND
    Treating adults with hypertension to a systolic blood pressure goal of <120 mmHg compared with <140 mmHg lowered the risk of mild cognitive impairment (MCI), according to findings of the SPRINT MIND trial [1].

    In the original SPRINT trial, targeting a systolic blood pressure of <120 mmHg resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause among patients at high risk for cardiovascular events without diabetes [2]. SPRINT MIND consequently evaluated the effect of intensive blood pressure control on risk of dementia. Geriatrist Dr Jeff Williamson (Wake Forest Baptist Medical Center, Winston-Salem, USA) presented the results.

    Participants were aged 50 years or older with hypertension but without diabetes or a history of stroke. They were randomised to a systolic blood pressure goal of <120 mmHg (intensive treatment; n=4,678) or <140 mmHg (standard treatment; n=4,683). During a median follow-up of 5.1 years, the primary cognitive outcome of adjudicated probable dementia occurred in 149 and 176 participants in the intensive and standard treatment group, respectively (HR 0.83). Dr Williamson speculated the study may have been underpowered to show an effect on dementia. Intensive blood pressure control did significantly reduce the risk of MCI (HR 0.81), as well as the combined rate of MCI or probable dementia (HR 0.85). The main MRI results, which had not yet been published, of intensive versus standard blood pressure control were as follows:

    • white matter lesion volume: 0.92 vs 1.45 cm3;
    • transformed white matter lesion volume: 0.15 vs 0.28 cm3 (P<0.001);
    • total brain volume change: -30.6 vs -26.9 mm3 (P=0.006).

    Dr Williamson concluded: “SPRINT MIND is the first randomised controlled trial intervention to show a reduction in the risk of MCI, without evidence that intensive blood pressure control harms cognition. This study demonstrates that a diverse population can be recruited, randomised, and assessed in follow-up for cognition over 5 years with acceptable assessment protocol adherence.”

    1. Williamson JD, et al. JAMA. 2019;321(6):553-61.
    2. Wright JT Jr, et al. N Engl J Med. 2015;373(22):2103-16.



    Posted on